Syneos Health and Aetion entered a partnership to provide regulatory-grade data and analytics-driven solutions designed to advance drug development and improve patient outcomes.
The partnership combines Syneos Health’s data collection and research services with Aetion Evidence Platform (AEP) to generate evidence through patient data curation and real-world data.
Syneos Health’s offerings, including its Biopharmaceutical Acceleration Model, Dynamic Assembly, and RWE Solutions, aims to enable biopharma companies to accelerate product development and patient access to new therapies; reduce risk through evidence-based decision-making; and demonstrate value to patients, regulators, payers, and health care providers. Aetion’s AEP analyzes data from the real world—including claims, electronic health records, registries, and clinical trial data—to produce transparent, rapid, and scientifically validated real-world evidence on the safety, effectiveness, and value of medical interventions.
Aetion will be a partner in the Syneos Health Dynamic Assembly network, an open ecosystem of data and technology collaborators committed to delivering fit-for-purpose solutions to strategically address the nuances of each customer engagement.
Similarly, Aetion partners with real world data providers across the globe to enable data access and accelerate time to insight on its platform. In 2020, Aetion became the first RWE company to establish an FDA COVID-19 research collaboration agreement and was selected by ICER as its preferred RWE partner and platform.
